Last update:

Medications news

Medications

Novo Nordisk study finds greater waist reduction with higher semaglutide dosage

A Novo Nordisk-designed trial, conducted at 68 international hospitals, specialist clinics, and medical centers with investigators from University of Texas Southwestern Medical Center and other institutions, reports greater ...

Medications

Unproven stroke treatment is no more effective than placebo, clinical trial finds

The first international trial of an unproven stroke treatment available in the U.S. has concluded that, while harmless, "perispinal" etanercept—injected into the spinal area—is no more effective than an inactive dummy ...

Medications

A forgotten opioid has resurfaced as a lethal street drug

Nitazenes—a class of highly potent synthetic opioids—are rapidly emerging as a major contributor to the overdose crisis, according to a Pain Medicine review published today by authors from Vanderbilt University Medical ...

Medications

Beta blockers: Why are celebrities name-checking this drug?

A little blue pill is creating a stir in Hollywood—and no, it's not Viagra. It's propranolol, a beta blocker originally designed for heart conditions, that's now making its way into dressing rooms, award ceremonies and ...

Medications

Taking semaglutide turns down food noise, research suggests

New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15–19 September) shows that individuals who are taking semaglutide for weight loss experience ...

Medications

Rivaroxaban comparable to warfarin in left ventricular blood clots

At three months of follow-up, patients hospitalized for a serious heart attack who were treated with the oral blood thinner rivaroxaban for a blood clot in the left ventricle did as well as similar patients who received standard ...

Medications

US approves new antibiotic for urinary tract infections

US health regulators have approved a new antibiotic to treat urinary tract infections, a problem affecting more than 100 million people around the world, mainly women, British pharmaceutical giant GSK said Tuesday.